Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates to address this metabolic–psychiatric interface. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.